Bandaram Pharma Packtech director NSK Aakarsh Raj resigns

0 min read     Updated on 05 Jun 2026, 05:33 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Mr. NSK Aakarsh Raj resigned as Whole-time Director of Bandaram Pharma Packtech Limited effective June 5, 2026, citing personal reasons. The company confirmed the resignation is immediate and complies with SEBI regulations.

powered bylight_fuzz_icon
42206612

*this image is generated using AI for illustrative purposes only.

Mr. NSK Aakarsh Raj has resigned as Whole-time Director of Bandaram Pharma Packtech Limited effective June 5, 2026. The resignation, tendered due to other professional and personal reasons, was accepted by the Board and is effective immediately.

The disclosure was made to BSE Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that there are no material reasons for the resignation other than those stated in the letter.

Details of Resignation

The company provided the following specifics regarding the change in its filing:

Particulars Details
Director Name Mr. NSK Aakarsh Raj
Designation Whole-time Director
Reason for Change Resignation as Whole-time director of the Company
Date of Cessation 05.06.2026
Terms of Appointment NA

Deepak Bandaram, Chairman and Managing Director, signed the regulatory disclosure submitted to the exchange. The company has requested that necessary forms be submitted to the Registrar of Companies and the Stock Exchange to record the change.

Historical Stock Returns for Bandaram Pharma Packtech

1 Day5 Days1 Month6 Months1 Year5 Years
-1.16%+4.53%+17.45%-21.08%-24.70%+26.46%

Who will be appointed to replace Mr. NSK Aakarsh Raj, and how will this impact the company's strategic direction?

What are the potential short-term operational risks for Bandaram Pharma Packtech following the sudden departure of a Whole-time Director?

How might the market react to this leadership change in terms of stock price and investor confidence?

Bandaram Pharma Packtech
View Company Insights
View All News
like20
dislike

Bandaram Pharma reports FY26 profit, auditors flag subsidiary issues

2 min read     Updated on 31 May 2026, 01:45 AM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Bandaram Pharma Packtech Limited reported a consolidated net profit of ₹44.81 lakh for the financial year ended March 31, 2026, while standalone operations recorded a net loss of ₹115.91 lakh. The board approved the audited financial results on May 30, 2026. Statutory auditors M/s. M.M. Reddy & Co. issued an unmodified opinion on standalone results but a modified opinion on consolidated results due to accounting irregularities at subsidiary VSR Paper and Packaging Limited, specifically regarding the netting off of trade receivables and payables amounting to ₹1,240.80 lakh without sufficient documentation. The board also appointed M/s. MGR & Co. as internal auditors for FY 2026-27.

powered bylight_fuzz_icon
41717570

*this image is generated using AI for illustrative purposes only.

Bandaram Pharma Packtech Limited reported a consolidated net profit of ₹44.81 lakh for the financial year ended March 31, 2026, while its standalone operations recorded a net loss of ₹115.91 lakh for the same period. The company's board approved the audited financial results for the quarter and year ended March 31, 2026, at a meeting held on May 30, 2026. The statutory auditors, M/s. M.M. Reddy & Co., issued an unmodified opinion on the standalone financial results but provided a modified opinion on the consolidated results, citing significant accounting irregularities at subsidiary VSR Paper and Packaging Limited.

The subsidiary recorded purchase and sale transactions with certain parties through the same ledger accounts, resulting in the netting off of trade receivables and payables. The auditors noted that management provided inadequate supporting documentation to establish the commercial substance of this treatment or the legal right of set-off for certain adjustments. Consequently, the auditors stated they were unable to obtain sufficient appropriate audit evidence regarding the completeness and accuracy of the adjusted trade receivables and payables, the validity of underlying transactions, and the consequential impact on the consolidated financial statements.

Financial Performance

For the full year FY26, the company reported a consolidated total income of ₹6,294.12 lakh, compared to ₹3,705.77 lakh in the previous year. On a standalone basis, total income stood at ₹1,096.82 lakh, down from ₹1,232.22 lakh in FY25. The consolidated figures include the financials of subsidiaries VSR Paper and Packaging Limited and Craftsmart Products Private Limited.

Key Financials (FY26)

Metric Standalone (₹ in lakh) Consolidated (₹ in lakh)
Total Income 1,096.82 6,294.12
Total Expenses 1,212.84 6,249.99
Net Profit/(Loss) (115.91) 44.81
Earnings Per Share (Basic) (0.64) 0.25

Auditor Observations

The auditors highlighted that sundry debtors and creditors amounting to ₹1,240.80 lakh were adjusted by offsetting with various parties in the subsidiary's books. Consequently, the auditors could not determine whether adjustments were necessary to the reported consolidated profit of ₹44.13 lakh or total assets of ₹7,586.25 lakh. The management stated that it has taken note of the auditors' opinion and will take necessary actions subsequently.

Board Decisions

Alongside the results, the board appointed M/s. MGR & Co., Chartered Accountants, as internal auditors for the financial year 2026-27. The company confirmed that the financial statements were prepared in compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015, and Indian Accounting Standards.

Historical Stock Returns for Bandaram Pharma Packtech

1 Day5 Days1 Month6 Months1 Year5 Years
-1.16%+4.53%+17.45%-21.08%-24.70%+26.46%

What specific remedial actions does management plan to take to address the accounting irregularities identified at VSR Paper and Packaging Limited?

How will the modified audit opinion and potential restatements impact the company's ability to secure financing or maintain investor confidence in FY27?

Will the company restate its consolidated financial statements for FY26 once the audit evidence regarding the subsidiary's trade receivables and payables is obtained?

Bandaram Pharma Packtech
View Company Insights
View All News
like16
dislike

More News on Bandaram Pharma Packtech

1 Year Returns:-24.70%